Furthermore, the rapid tumor growth in our animal models may have outpaced the time needed for immune cells to activate and infiltrate the tumor, limiting the therapeutic window for interventions like TGF-β inhibition and GITR agonism [55]. This evidence concerns the gene TGFB1 and neoplasm.